CHICAGO, June 11, 2026
Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Biopharma Holdings, Inc., announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a new patent application covering the use of KEVEYIS® (dichlorphenamide), the first FDA-approved treatment for Primary Periodic Paralysis (PPP). The patent is expected to provide intellectual property protection for KEVEYIS through 2039, reinforcing Xeris’ long-term commitment to patients living with this rare neuromuscular disorder. Following issuance, the company plans to submit the patent for inclusion in the FDA’s Orange Book, strengthening the product’s market exclusivity and supporting continued investment in treatment access and patient support programs.
Patent Protection Strengthens Long-Term KEVEYIS Strategy
The newly allowed patent application, titled “Compositions and Methods of Use,” covers the therapeutic use of KEVEYIS and represents a significant milestone in Xeris’ lifecycle management strategy. The company stated that the patent will help safeguard the only FDA-approved therapy specifically indicated for primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants. By extending protection through 2039, Xeris aims to ensure long-term availability of the therapy while supporting future investments in research, patient education, and disease management initiatives. The patent allowance also reflects the company’s continued efforts to strengthen its intellectual property portfolio around key commercial products.
KEVEYIS Addresses Significant Unmet Need in Rare Neuromuscular Disease
Primary Periodic Paralysis is a rare inherited disorder characterized by recurrent episodes of muscle weakness or temporary paralysis that can become progressively debilitating over time. Patients often experience unpredictable attacks that significantly impact mobility, daily functioning, and quality of life. KEVEYIS has demonstrated the ability to reduce the frequency, severity, and duration of PPP attacks, making it an important treatment option for affected individuals. Xeris emphasized that protecting the product’s intellectual property supports continued access to a therapy that remains critical for a highly underserved patient population with limited treatment alternatives.
Advertisement
Xeris Expands Focus on Rare Disease and Specialty Therapeutics
The patent development comes as Xeris continues to grow its portfolio of specialty and rare disease therapies. In addition to KEVEYIS, the company markets RECORLEV® for endogenous Cushing’s syndrome and GVOKE® for severe hypoglycemia, while advancing multiple pipeline programs including XP-8121, a Phase 3-ready once-weekly treatment for hypothyroidism. Company leadership noted that securing long-term patent protection for KEVEYIS aligns with Xeris’ broader strategy of delivering innovative therapies for patients with serious and underserved medical conditions. The new patent is expected to strengthen the commercial position of KEVEYIS while supporting continued growth across Xeris’ rare disease franchise.
Source: Xeris Pharmaceuticals press release
